VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

Blood

Volumn 114, Issue 21, 2009, Pages 4687-4695

  Arons, Evgeny ^a   Suntum, Tara ^a   Stetler Stevenson, Maryalice ^a   Kreitman, Robert J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; IMMUNOGLOBULIN; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE REARRANGEMENT; GENE SEQUENCE; GERM LINE; HAIRY CELL LEUKEMIA; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SOMATIC HYPERMUTATION; TREATMENT RESPONSE; VH 4 34 GENE; COMPLEMENTARITY DETERMINING REGION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; COMPLEMENTARITY DETERMINING REGIONS; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; PROGNOSIS;

EID: 73949120281     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-201731     Document Type: Article

References (72)

1. Cawley JC, Burns GF, Hayhoe FG. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4(6):547-559.
2. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol. 2003;16(1):41-56.
3. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinicopathological features of the variant form of hairy-cell leukemia. Leukemia. 2001;15(1):184-186.
4. Sainati L, Matutes E, Mulligan S, et al. A variant form of hairy-cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood. 1990;76(1):157-162.
5. Matutes E. Immunophenotyping and differential diagnosis of hairy-cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1051-1063.
6. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495.
7. Cessna MH, Hartung L, Tripp S, Perkins SL, Bahler DW. Hairy-cell leukemia variant - fact or fiction Am J Clin Pathol. 2005;123(1):132-138.
8. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy-cell leukemia: an intergroup study. J Clin Oncol. 1995;13(4):974-982.
9. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy-cell leukemia after cladribine treatment. Blood. 1998;92(6):1918- 1926.
10. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy-cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891-896.
11. Blasińska-Morawiec M, Robak T, Krykowski E, Hellmann A, Urbanska-Rys H. Hairy-cell leukemia-variant treated with 2-chlorodeoxyadenosine - a report of three cases. Leuk Lymphoma. 1997;25(3-4):381-385.
12. Tetreault SA, Robbins BA, Saven A. Treatment of hairy-cell leukemia-variant with cladribine. Leuk Lymphoma. 1999;35(3-4):347-354.
13. Quach H, Januszewicz H, Westerman D. Complete remission of hairy-cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica. 2005;90 Suppl:ECR26.
14. Imamura T, Ohtsuka E, Ogata M, et al. Successful induction of long-term remission using rituximab in a patient with refractory hairy-cell leukemia-Japanese variant. Int J Hematol. 2004;80(5):432-434.
15. Goldaniga M, Guffanti A, Gianelli U, Magni M, Lambertenghi Deliliers G, Baldini L. Clinical and molecular complete remission in a case of variant hairy-cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab. Haematologica. 2004;89(11):138e.
16. Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy-cell leukemia variant with rituximab. Leuk Lymphoma. 2005;46(8):1229-1232.
17. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345(4):241-247.
18. Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy-cell leukemia. Br J Haematol. 2006;133(5):504-512.
19. Thorsélius M, Walsh SH, Thunberg U, Hagberg H, Sundstrom C, Rosenquist R. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy-cell leukemia. Leuk Res. 2005;29(2):153-158.
20. Vanhentenrijk V, Tierens A, Wlodarska I, Verhoef G, Wolf-Peeters CD. V(H) gene analysis of hairy-cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin. Leukemia. 2004;18(10):1729-1732.
21. Maloum K, Magnac C, Azgui Z, et al. VH gene expression in hairy-cell leukaemia. Br J Haematol. 1998;101(1):171-178.
22. Miranda RN, Cousar JB, Hammer RD, Collins RD, Vnencak-Jones CL. Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy-cell leukemia are composed of memory B lymphocytes. Hum Pathol. 1999;30(3):306-312.
23. Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy-cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood. 2001;98(4):1174-1181.
24. Martín-Jiménez P, Garcia-Sanz R, Gonzalez D, et al. Molecular characterization of complete and incomplete immunoglobulin heavy chain gene rearrangements in hairy-cell leukemia. Clin Lymphoma Myeloma. 2007;7(9):573-579.
25. Forconi F, Sozzi E, Rossi D, et al. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy-cell leukemia. Haematologica. 2008;93(5):697-705.
26. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed., Vol 2. Lyon, France: WHO Press; 2008.
27. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317.
28. IMGT database. The International Immunogenetics Information System. http://imgt.cines.fr/. Accessed September 22, 2009.
29. VBASE2 database. http://www.vbase2.org/). Accessed September 22, 2009.
30. Dunphy CH. Reaction patterns of TRAP and DBA.44 in hairy-cell leukemia, hairy-cell variant, and nodal and extranodal marginal zone B-cell lymphomas. Appl Immunohistochem Mol Morphol. 2008;16(2):135-139.
31. Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol. 2005;124(3):414-420.
32. Brezinschek HP, Foster SJ, Brezinschek RI, Dorner T, Domiati-Saad R, Lipsky PE. Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J Clin Invest. 1997;99(10):2488-2501.
33. Logtenberg T, Schutte ME, Inghirami G, et al. Immunoglobulin VH gene expression in human B cell lines and tumors: biased VH gene expression in chronic lymphocytic leukemia. Int Immunol. 1989;1(4):362-366.
34. Stewart AK, Huang C, Stollar BD, Schwartz RS. High-frequency representation of a single VH gene in the expressed human B-cell repertoire. J Exp Med. 1993;177(2):409-418.
35. Kraj P, Friedman DF, Stevenson F, Silberstein LE. Evidence for the overexpression of the VH4-34 (VH4.21) Ig gene segment in the normal adult human peripheral blood B-cell repertoire. J Immunol. 1995;154(12):6406-6420.
36. Stevenson FK, Smith GJ, North J, Hamblin TJ, Glennie MJ. Identification of normal B-cell counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br J Haematol. 1989;72(1):9-15.
37. Hsu FJ, Levy R. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma. Blood. 1995;86(8):3072-3082.
38. Sato Y, Ichimura K, Tanaka T, et al. Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol. 2008;61(3):377-381.
39. Montesinos-Rongen M, Kuppers R, Schluter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155(6):2077- 2086.
40. Deane M, Baker BW, Norton JD. Immunoglobulin VH4 gene usage in B lymphoid leukaemias. Br J Haematol. 1993;84(2):242-249.
41. + B-cell chronic lymphocytic leukemia and displaying autoantibody activity. Blood. 1993;82(10):3103-3112.
42. Maloum K, Magnac C, Pritsch O, Binet JL, Merle-Beral H, Dighiero G. Skewed rearrangement of the VH4-21 gene during pre-B acute lymphoblastic leukemia. Leuk Lymphoma. 1995;17(5-6):435-441.
43. Rettig MB, Vescio RA, Cao J, et al. VH gene usage in multiple myeloma: complete absence of the VH4.21 (VH4-34) gene. Blood. 1996;87(7):2846-2852.
44. + myeloma protein with weak autoreactivity. Haematologica. 2007;92(5):690-693.
45. González D, González M, Balanzategui A, et al. Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. Haematologica. 2005;90(7):906-913.
46. Bhat NM, Lee LM, van Vollenhoven RF, Teng NN, Bieber MM. VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype. J Rheumatol. 2002;29(10):2114-2121.
47. Pascual V, Victor K, Spellerberg M, Hamblin TJ, Stevenson FK, Capra JD. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol. 1992;149(7):2337-2344.
48. Riboldi P, Gaidano G, Schettino EW, et al. Two acquired immunodeficiency syndrome-associated Burkitt's lymphomas produce specific anti-i IgM cold agglutinins using somatically mutated VH4-21 segments. Blood. 1994;83(10):2952-2961.
49. Silberstein LE, Jefferies LC, Goldman J, et al. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood. 1991;78(9):2372-2386.
50. Bhat NM, Bieber MM, Hsu FJ, et al. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies, II. Clin Exp Immunol. 1997;108(1):151-159.
51. Bhat NM, Bieber MM, Stevenson FK, Teng NN. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Clin Exp Immunol. 1996;105(1):183-190.
52. Bhat NM, Bieber MM, Teng NN. Cytotoxicity of murine B lymphocytes induced by human VH4-34 (VH4.21) gene-encoded monoclonal antibodies. Clin Immunol Immunopathol. 1997;84(3):283-289.
53. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol. 1999;163(9):5133-5144.
54. Childs RA, Dalchau R, Scudder P, Hounsell EF, Fabre JW, Feizi T. Evidence for the occurrence of O-glycosidically linked oligosaccharides of poly-N-acetyllactosamine type on the human leukocyte common antigen. Biochem Biophys Res Commun. 1983;110(2):424-431.
55. Bhat NM, Bieber MM, Chapman CJ, Stevenson FK, Teng NN. Human antilipid A monoclonal antibodies bind to human B cells and the i antigen on cord red blood cells. J Immunol. 1993;151(9):5011-5021.
56. van Vollenhoven RF, Bieber MM, Powell MJ, et al. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics. J Rheumatol. 1999;26(8):1727-1733.
57. Owens GP, Burgoon MP, Anthony J, Kleinschmidt-DeMasters BK, Gilden DH. The immunoglobulin G heavy chain repertoire in multiple sclerosis plaques is distinct from the heavy chain repertoire in peripheral blood lymphocytes. Clin Immunol. 2001;98(2):258-263.
58. Smith-Jensen T, Burgoon MP, Anthony J, Kraus H, Gilden DH, Owens GP. Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology. 2000;54(6):1227-1232.
59. Colombo M, Dono M, Gazzola P, et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol. 2000;164(5):2782-2789.
60. Parr TB, Johnson TA, Silberstein LE, Kipps TJ. Anti-B-cell autoantibodies encoded by VH 4-21 genes in human fetal spleen do not require in vivo somatic selection. Eur J Immunol. 1994;24(12):2941-2949.
61. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
62. Mercieca J, Matutes E, Moskovic E, et al. Massive abdominal lymphadenopathy in hairy-cell leukaemia: a report of 12 cases. Br J Haematol. 1992;82(3):547-554.
63. Mercieca J, Puga M, Matutes E, Moskovic E, Salim S, Catovsky D. Incidence and significance of abdominal lymphadenopathy in hairy-cell leukaemia. Leuk Lymphoma. 1994;14 Suppl 1:79-83.
64. Mercieca J, Matutes E, Emmett E, Coles H, Catovsky D. 2-Chlorodeoxyadenosine in the treatment of hairy-cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol. 1996;93(2):409-411.
65. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23(27):6719-6729.
66. Saven A, Piro LD. Complete remissions in hairy-cell leukemia with 2-chlorodeoxyadenosine after failure with 2-deoxycoformycin. Ann Intern Med. 1993;119(4):278-283.
67. Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy-cell leukemia. Leuk Lymphoma. 1994;14 Suppl 1:121-125.
68. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy-cell leukemia patients. A French retrospective study of 238 patients. Leukemia. 2003;17(1):45-51.
69. Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy-cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005;106(1):241-246.
70. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy-cell leukemia with purine analogs - A report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104(11):2442-2448.
71. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy-cell leukemia. Blood. 2006;107(12):4658-4662.
72. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy-cell leukemia. Cancer. 2007;110(10):2240-2247.